Skip to main content
Figure 5 | Journal of Experimental & Clinical Cancer Research

Figure 5

From: BAP31, a promising target for the immunotherapy of malignant melanomas

Figure 5

LDH release assay for cytotoxicity of CTLs from mBAP31 vaccinated mice against murine cancer cell lines. Cytotoxic activities of CTLs isolated from the splenocytes of the p-LAMP/mBAP31 vaccinated C57BL/6 mice (H-2b) against mBAP31 peptides pulsed mouse colon cancer cell lines CT26 (H-2d), 2E8 (mBAP31 depleted B16 cells, H-2b) and B16 (H-2b) were detected by LDH release assay at effector-to-target ratio of 50:1. Peptides used were indicated in abscissa (A-C). Cytotoxic activities of CTLs from p-LAMP/mBAP31 (), p-mBAP31 (□) or PBS () vaccinated C57BL/6 mice (H-2b) against B16 cells pulsed with mBAP31149–157 expressing both H-2b and mBAP31 (D), 2E8 cells (mBAP31 depleted B16 cells) pulsed with mBAP31149–157 expressing H-2b but much lower mBAP31 than B16 cells (E), CT26 cells pulsed with mBAP31149–157 expressing H-2d and mBAP31 (F), B16 cells expressing both H-2b and mBAP31 (G), 2E8 cells expressing H-2b but much lower mBAP31 than B16 cells (H) and CT26 cells expressing H-2d and mBAP31 (I).

Back to article page